Skip to main content
IMMX
NASDAQ Life Sciences

Immix Biopharma Reports 89% Complete Response Rate in NEXICART-2, Potential to Reach 98%

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
8
Price
$11.58
Mkt Cap
$820.556M
52W Low
$1.99
52W High
$15.1
52W Position info
482% above low
Off High info
23% below high
Rel. Volume info
0.6× avg
Market data snapshot near publication time

IMMX has more than doubled off its 52-week low of $1.99.

Summary

An 89% complete response rate was reported across all 45 NEXICART-2 patients, with MRD-negativity suggesting the rate could reach 98%. No relapses or serious safety signals were observed. Final readout and BLA submission are planned for mid-2027.


Key Events · Product Development and Regulatory · IMMX

  • 89% Complete Response Rate

    Across all 45 relapsed/refractory AL Amyloidosis patients in the Phase 2 NEXICART-2 trial, NXC-201 produced an 89% (40/45) complete response rate as assessed by an independent review committee.

  • MRD-Negativity Suggests 98% Potential

    All 25 new patients are either in CR or MRD-negative. In four pending patients already MRD-negative, bone marrow MRD-negativity predicts future CR, potentially increasing the CR rate up to 98% (44/45).

  • No Relapses or Serious Safety Signals

    No relapses have been observed for any patient who reached CR or MRD-negativity. No neurotoxicity or enterocolitis has been observed to date, with safety data consistent with prior reports.

  • Registrational Path to BLA

    NEXICART-2 is a fully enrolled, 45-patient multi-site U.S. Phase 2 trial with a registrational design. Final readout and BLA submission are planned for mid-2027.


Analysis · IMMX · Life Sciences

Interim data from the fully enrolled 45-patient Phase 2 NEXICART-2 trial show an 89% complete response rate in relapsed/refractory AL Amyloidosis, with MRD-negativity suggesting the rate could climb to 98%. An independent review committee assessed the results, and no relapses, neurotoxicity, or enterocolitis have been observed to date. This registrational-design trial supports a final readout and BLA submission in mid-2027. For a company with a $820M market cap and $232M in cash, this data meaningfully de-risks the lead asset and supports a potential best-in-class profile in a $6.6B market.

How filings like this one have moved

In the 30 days to Nov 12, 2026, 47.3% of the 1873 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.17%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, IMMX was trading at $11.58 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $820.6M. The 52-week trading range was $1.99 to $15.10. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

IMMX - Latest Insights

IMMX
Nov 12, 2026, 4:15 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $8.07
Real-time Price: $7.84 info
Change: -$0.230 (-3%) info
Market Cap: $649.959M info
IMMX
Nov 12, 2026, 4:05 PM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $8.07
Real-time Price: $7.84 info
Change: -$0.230 (-3%) info
Market Cap: $649.959M info
IMMX
Sep 30, 2026, 5:10 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $10.40
Real-time Price: $7.84 info
Change: -$2.56 (-25%) info
Market Cap: $649.959M info
IMMX
Sep 29, 2026, 7:22 AM EDT
Filing Type: 424B5
Importance Score:
7
Price at Filing: $12.15
Real-time Price: $7.84 info
Change: -$4.31 (-35%) info
Market Cap: $649.959M info
IMMX
Aug 07, 2026, 5:05 PM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $9.81
Real-time Price: $7.84 info
Change: -$1.97 (-20%) info
Market Cap: $649.959M info